Syndax Pharmaceuticals Inc (SNDX) earnings date
Mar 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 35 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | after close | 30 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | after close | 35 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | after close | 35 | 8-K |
| Q4 FY2024 | Mon, Mar 3, 2025 | before open | 62 | 8-K |
What they guided beta
| Q3 FY2026 | "The Company expects to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:" exhibit |
| Q3 FY2026 | "The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "The Company expects the RAVEN trial to initiate in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "The Company expects the MenTain Phase 2 trial to initiate in the first quarter of 2027." exhibit |
| Q3 FY2026 | "The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027." exhibit |
| Q2 FY2026 | "We also have multiple near-term catalysts with Niktimvo Phase 2 data in IPF and frontline cGVHD expected in the fourth quarter, plus additional practice-informing and" exhibit |
| Q2 FY2026 | "The Company expects to have a major presence at upcoming medical meetings in the second half of 2026 with the presentation of new/updated revumenib data including:" exhibit |
| Q2 FY2026 | "The Company expects the RAVEN trial to initiate in the second half of 2026." exhibit |
| Q2 FY2026 | "The Company expects the MenTain Phase 2 trial to initiate around the end of 2026." exhibit |
| Q2 FY2026 | "The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SNDX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SNDX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SNDX/"><img src="https://veritasdata.dev/embed/SNDX.svg" alt="SNDX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SNDX/)
Script
<script async src="https://veritasdata.dev/embed/SNDX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SNDX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.